keyword
MENU ▼
Read by QxMD icon Read
search

metastatic prostate cancer

keyword
https://www.readbyqxmd.com/read/29455299/prostate-specific-membrane-antigen-in-breast-cancer-a-comprehensive-evaluation-of-expression-and-a-case-report-of-radionuclide-therapy
#1
Yuri Tolkach, Heidrun Gevensleben, Ralph Bundschuh, Aydan Koyun, Daniela Huber, Christina Kehrer, Thomas Hecking, Mignon-Denise Keyver-Paik, Christina Kaiser, Hojjat Ahmadzadehfar, Markus Essler, Walther Kuhn, Glen Kristiansen
PURPOSE: Prostate-specific membrane antigen (PSMA), a protein product of the folate hydrolase 1 (FOLH1) gene, is gaining increasing acceptance as a target for positron emission tomography/computer tomography (PET/CT) imaging in patients with several cancer types, including breast cancer. So far, PSMA expression in breast cancer endothelia has not been sufficiently characterized. METHODS: This study comprised 315 cases of invasive carcinoma of no special type (NST) and lobular breast cancer (median follow-up time 9...
February 17, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29455168/experiences-of-australian-men-diagnosed-with-advanced-prostate-cancer-a-qualitative-study
#2
Suzanne K Chambers, Melissa K Hyde, Kirstyn Laurie, Melissa Legg, Mark Frydenberg, Ian D Davis, Anthony Lowe, Jeff Dunn
OBJECTIVE: To explore men's lived experience of advanced prostate cancer (PCa) and preferences for support. DESIGN: Cross-sectional qualitative study applying open-ended surveys and interviews conducted between June and November 2016. Interviews audio-recorded and transcribed verbatim and analysed from an interpretive phenomenological perspective. SETTING: Australia, nation-wide. PARTICIPANTS: 39 men diagnosed with advanced PCa (metastatic or castration-resistant biochemical regression) were surveyed with 28 men subsequently completing a semistructured in depth telephone interview...
February 17, 2018: BMJ Open
https://www.readbyqxmd.com/read/29454590/understanding-how-prostate-cancer-patients-value-the-current-treatment-options-for-metastatic-castration-resistant-prostate-cancer
#3
Tarik Benidir, Karen Hersey, Antonio Finelli, Rob Hamilton, Anthony M Joshua, Girish Kulkarni, Alexandre Zlotta, Neil Fleshner
Several new compounds are now available for castration resistant prostate cancer (CRPC). Individual costs range between $40,000 and $93,000 with mean survival extensions from 2.4 to 4.8 months. Currently, it remains unclear how patients with prostate cancer (PCa) value the effect of these therapies in the setting of CRPC. OBJECTIVE: To assess patient understanding of core cancer concepts, opinions on the cost and overall benefit of CRPC drugs, whether out-of-pocket costs would change opinions and whether patients would ultimately opt out of CRPC drug treatment for an end-of-life (EOL) premium...
February 14, 2018: Urologic Oncology
https://www.readbyqxmd.com/read/29454548/correlation-between-molecular-tumor-volume-evaluated-with-68-ga-psma-pet-ct-and-prostatic-specific-antigen-levels
#4
S Medina-Ornelas Sevastián, O García-Pérez Francisco, Y Hernández-Pedro Norma, E Arellano-Zarate Angélica, L Abúndiz-López Blanca
OBJECTIVE: To investigate the association between prostatic-specific antigen (PSA) levels and molecular tumor volume (MTV) measured in the68 Ga-PSMA PET/CT, both done in a short period of time, in prostate cancer patients with biochemical failure. METHODS: Eighty-four patients who underwent68 Ga-PSMA PET/CT and measurement of PSA levels in the same week (trigger-PSA) were studied in this retrospective analysis. MTV was calculated from the sum of the metastatic lesions...
February 14, 2018: Revista Española de Medicina Nuclear e Imagen Molecular
https://www.readbyqxmd.com/read/29453313/multigene-profiling-of-ctcs-in-mcrpc-identifies-a-clinically-relevant-prognostic-signature
#5
Udit Singhal, Yugang Wang, James Henderson, Yashar S Niknafs, Yuanyuan Qiao, Amy Gursky, Alexander Zaslavsky, Jae-Seung Chung, David C Smith, R Jeffrey Karnes, S Laura Chang, Felix Y Feng, Ganesh S Palapattu, Russell S Taichman, Arul M Chinnaiyan, Scott A Tomlins, Todd M Morgan
The trend towards precision-based therapeutic approaches dictated by molecular alterations offers substantial promise for men with metastatic castration resistant prostate cancer (mCRPC). However, current approaches for molecular characterization are primarily tissue based, necessitating serial biopsies to understand changes over time and are limited by the challenges inherent to extracting genomic material from predominantly bone metastases. Therefore, a circulating tumor cell (CTC)-based assay was developed to determine gene expression across a panel of clinically relevant and potentially actionable prostate cancer related genes...
February 16, 2018: Molecular Cancer Research: MCR
https://www.readbyqxmd.com/read/29450905/a-tramp-derived-orthotopic-prostate-syngeneic-tops-cancer-model-for-investigating-anti-tumor-treatments
#6
Justin Lardizabal, Jun Ding, Zahid Delwar, Paul S Rennie, William Jia
BACKGROUND: Patients with advanced prostate cancer have limited curative options, therefore new treatments are needed. Mouse models play a pivotal role in the discovery and development of new treatments. In the present study, a TRAMP-derived Orthotopic Prostate Syngeneic (TOPS) mouse model was developed and found to provide a consistent means of monitoring tumor and metastatic responses to novel treatments. METHODS: The mouse TOPS model was generated using luciferase transduced TRAMP-C2 prostate cancer cells that were orthotopically injected into Bl6 mice by ultrasound guidance...
February 16, 2018: Prostate
https://www.readbyqxmd.com/read/29446748/anti-oxidants-as-chemopreventive-agents-in-prostate-cancer-a-gap-between-preclinical-and-clinical-studies
#7
Monireh Mohsenzadegan, Farhad Seif, Mohammad Morad Farajollahi, Majid Khoshmirsafa
BACKGROUND: Tumor cells may be expressed as a result of oxidative stress. The extent of oxidative stress correlates with aggressive and metastatic potency of cancer. OBJECTIVE: One simple way to control prostate cancer is through chemoprevention which refers to the administration of natural or synthetic agents to block, reverse, or delay the process of carcinogenesis. The most chemopreventive agents are antioxidants in the nature. METHODS: In this review, we summarized the effects of dietary antioxidants with a focus on their molecular mechanisms and possible roles in the treatment of prostate cancer cells...
February 13, 2018: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/29445461/metastatic-prostate-cancer-with-bone-marrow-infiltration-mimicking-multiple-myeloma
#8
Pankaj Mathur, Daisy Alapat, Manoj Kumar, Sharmilan Thanendrarajan
Concomitant diagnosis of metastatic prostate cancer and a multiple myeloma in older male patients is challenging as both malignancies are usually associated with bone lesions. Exact knowledge, experience, and an interdisciplinary approach are required in order to differentiate between both malignancies and determine the exact treatment strategy.
February 2018: Clinical Case Reports
https://www.readbyqxmd.com/read/29439820/germline-dna-repair-gene-mutations-and-outcomes-in-men-with-metastatic-castration-resistant-prostate-cancer-receiving-first-line-abiraterone-and-enzalutamide
#9
Emmanuel S Antonarakis, Changxue Lu, Brandon Luber, Chao Liang, Hao Wang, Yan Chen, John L Silberstein, Danilo Piana, Zhao Lai, Yidong Chen, William B Isaacs, Jun Luo
BACKGROUND: Inherited DNA-repair gene mutations are more prevalent in men with advanced prostate cancer than previously thought, but their clinical implications are not fully understood. OBJECTIVE: To investigate the clinical significance of germline DNA-repair gene alterations in men with metastatic castration-resistant prostate cancer (mCRPC) receiving next-generation hormonal therapy (NHT), with a particular emphasis on BRCA/ATM mutations. DESIGN, SETTING, AND PARTICIPANTS: We interrogated 50 genes for pathogenic or likely pathogenic germline mutations using leukocyte DNA from 172 mCRPC patients beginning treatment with first-line NHT with abiraterone or enzalutamide...
February 10, 2018: European Urology
https://www.readbyqxmd.com/read/29439298/a-rare-cause-of-pancreatic-head-mass-metastatic-prostate-cancer-a-case-report-and-review-of-literature
#10
Khalil Aloreidi, Robert T Lapp
Metastases to the pancreas account for less than 5 percent of all malignancies affecting the pancreas. The most common secondary malignancy of the pancreas is renal cell carcinoma. We report a patient presented with abdominal pain and weight loss. Computed tomography (CT) imaging showed pancreatic head mass. Biopsy from the mass showed prostate metastasis after 13 years from radical prostatectomy and Leuprolide therapy. This case demonstrates a rare location for prostate metastasis which was the pancreas. To our knowledge there are only six cases reported in literature...
January 2018: South Dakota Medicine: the Journal of the South Dakota State Medical Association
https://www.readbyqxmd.com/read/29438990/nuclear-receptor-lrh-1-functions-to-promote-castration-resistant-growth-of-prostate-cancer-via-its-promotion-of-intratumoral-androgen-biosynthesis
#11
Lijia Xiao, Yuliang Wang, Kexin Xu, Hao Hu, Zhenyu Xu, Dinglan Wu, Zhu Wang, Wenxing You, Chi-Fai Ng, Shan Yu, Franky Leung Chan
Targeting of steroidogenic enzymes (e.g. abiraterone acetate targeting CYP17A1) has been developed as a novel therapeutic strategy against metastatic castration-resistant prostate cancer (CRPC). However, resistance to steroidal inhibitors inevitably develops in patients, the mechanisms of which remain largely unknown. Liver receptor homolog-1 (LRH-1, NR5A2) is a nuclear receptor, originally characterized as an important regulator of some liver-specific metabolic genes. Here we report that LRH-1, which exhibited an increased expression pattern in high-grade prostate cancer and CRPC xenograft models, functions to promote de novo androgen biosynthesis via its direct transactivation of several key steroidogenic enzyme genes, elevating intratumoral androgen levels and reactivating AR signaling in CRPC xenografts as well as abiraterone-treated CRPC tumors...
February 8, 2018: Cancer Research
https://www.readbyqxmd.com/read/29436722/the-prognosis-of-different-distant-metastases-pattern-in-prostate-cancer-a-population-based-retrospective-study
#12
Jiafeng Shou, Qi Zhang, Shuai Wang, Dahong Zhang
BACKGROUND: The present of metastases is a poor prognostic factor in prostate cancer, but the prognostic impact of different distant metastases pattern is unclear. The aim of this study is to investigate the impact of different distant metastases pattern on the survival of patients with stage IV prostate cancer. METHODS: Data queried for this study include prostate cancer (2010-2014) from the Surveillance, Epidemiology, and End Results (SEER) program. Metastatic distribution information was provided for bone, brain, liver and lung...
February 13, 2018: Prostate
https://www.readbyqxmd.com/read/29436390/identification-of-galeterone-and-abiraterone-as-inhibitors-of-dehydroepiandrosterone-sulfonation-catalyzed-by-human-hepatic-cytosol-sult2a1-sult2b1b-and-sult1e1
#13
Caleb K Y Yip, Sumit Bansal, Siew Ying Wong, Aik Jiang Lau
Galeterone and abiraterone acetate are anti-androgens developed for the treatment of metastatic castration-resistant prostate cancer. In the present study, we investigated the effect of these drugs on dehydroepiandrosterone (DHEA) sulfonation catalyzed by human liver and intestinal cytosols and human recombinant sulfotransferase enzymes (SULT2A1, SULT2B1b, and SULT2E1), and compared their effects to those of other anti-androgens (cyproterone acetate, spironolactone, and danazol). Each of these chemicals (10 μM) inhibited DHEA sulfonation catalyzed by human liver and intestinal cytosols...
February 7, 2018: Drug Metabolism and Disposition: the Biological Fate of Chemicals
https://www.readbyqxmd.com/read/29434991/mechanism-of-the-anti-angiogenic-effect-of-avemar-on-tumor-cells
#14
Nilüfer Gülmen Imir, Esra Aydemir, Ece Şimşek
Avemar, a derivative of fermented wheat germ extract, is a non-toxic and natural compound that is used as a dietary supplement by cancer patients undergoing chemotherapy and radiotherapy. Avemar has numerous biological activities, and several recent studies have reported that it may also have metastatic and anti-angiogenic effects. In the present study, the mechanism of the anti-angiogenic effect of Avemar on human cancer cells was investigated. The human cell lines NCI-N87 (gastric tubular adenocarcinoma), PC3 (prostate carcinoma), HeLa (endocervical adenocarcinoma) and A549 (lung adenocarcinoma) were treated with various doses (400, 800, 1,600 and 3,200 µg/ml) of Avemar, and the changes in mRNA and protein levels of two important markers of angiogenesis, vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (Cox-2), were assessed by reverse transcription-quantitative polymerase chain reaction and ELISA...
February 2018: Oncology Letters
https://www.readbyqxmd.com/read/29434990/abiraterone-acetate-withdrawal-syndrome-speculations-on-the-underlying-mechanisms
#15
Tomonori Kato, Akira Komiya, Joji Yuasa, Kanya Kaga, Mayuko Kaga, Satoko Kojima, Yukio Naya, Shigeo Isaka
A 72-year-old man initially presented with lumbar and right chest pain, but was later found out to also have an elevated prostate-specific antigen (PSA) level at 2,000.0 ng/ml. Further evaluation disclosed metastatic prostate cancer involving the bones and lymph nodes. The patient was initially treated with combined androgen blockade (CAB) with leuprolide acetate and bicalutamide. After 6 months of CAB, the patient's PSA level began to rise from the nadir (85.1 ng/ml) to 113.3 ng/ml. Bicalutamide was withdrawn in anticipation of anti-androgen withdrawal syndrome and the PSA level declined temporally...
February 2018: Oncology Letters
https://www.readbyqxmd.com/read/29434673/practical-differences-between-luteinizing-hormone-releasing-hormone-agonists-in-prostate-cancer-perspectives-across-the-spectrum-of-care
#16
REVIEW
Davide Meani, Mladen Solarić, Harri Visapää, Rose-Marie Rosén, Robert Janknegt, Majana Soče
Background: Androgen deprivation therapy (ADT) with luteinizing hormone-releasing hormone (LHRH) agonists is well established for the treatment of men with metastatic prostate cancer. As clear differences in efficacy, safety, or tolerability between the available LHRH agonists are lacking, the healthcare management team needs to look to practical differences between the formulations when selecting therapy for their patients. Moreover, as the economic burden of prostate cancer rises alongside earlier diagnosis and improved survival, the possibility for cost savings by using products with specific features is growing in importance...
February 2018: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/29433837/effect-of-enzymatic-pre-treatment-of-microalgae-extracts-on-their-anti-tumor-activity
#17
Asma Jabeen, Brandon Reeder, Soleiman Hisaindee, Salman Ashraf, Naeema Al Darmaki, Sinan Battah, Sulaiman Al-Zuhair
BACKGROUND: There is an increasing need to find natural bioactive compounds for pharmaceutical applications, because they have less harmful side effects compared to their chemical alternatives. Microalgae (MA) have been identified as a promising source for these bioactive compounds, and this work aimed to evaluate the anti-proliferative effects of semi-purified protein extracted from MA against several tumor cell lines. METHODS: Tested samples comprised MA cell extracts treated with cellulase and lysozyme, prior to extraction...
December 2017: Biomedical Journal
https://www.readbyqxmd.com/read/29432079/first-line-treatment-of-hormone-sensitive-metastatic-prostate-cancer-is-there-a-single-standard-of-care
#18
Che-Kai Tsao, William K Oh
No abstract text is available yet for this article.
February 12, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29431639/cxcl12%C3%AE-%C3%A2-promotes-development-of-metastatic-castration-resistant-prostate-cancer-by-induction-of-cancer-stem-cell-and-neuroendocrine-phenotypes
#19
Younghun Jung, Frank C Cackowski, Kenji Yumoto, Ann Decker, Jingcheng Wang, Jinkoo Kim, Eunsohl Lee, Yugang Wang, Jae-Seung Chung, Amy M Gursky, Paul H Krebsbach, Kenneth J Pienta, Todd M Morgan, Russell S Taichman
There is evidence that cancer stem-like cells (CSC) and neuroendocrine (NE) behavior play critical roles in the pathogenesis and clinical course of metastatic castration-resistant prostate cancer (m-CRPC). However, there is limiting mechanistic understanding of how CSC and NE phenotypes impact the development of m-CRPC, which could improve opportunities to identify useful biomarkers and therapeutics. In this study, we explored the role of the intracellular chemokine CXCL12γ in CSC induction and NE differentiation and its impact on m-CRPC...
February 5, 2018: Cancer Research
https://www.readbyqxmd.com/read/29431540/pharmacokinetic-pharmacodynamic-drug-evaluation-of-enzalutamide-for-treating-prostate-cancer
#20
Jeong Hee Hong
Enzalutamide is the first approved second-generation androgen receptor (AR) antagonist in the treatment of metastatic castration-resistant prostate cancer (mCRPC) with or without docetaxel-based chemotherapy. Over the past 5 years, a number of attempts were made to determine the efficacy of enzalutamide in the different clinical settings. Areas covered: A literature search was performed at the PubMed, Embase, and Web of Science database to collect the most relevant and impactful studies, including basic science investigations, clinical trials, and reviews...
February 12, 2018: Expert Opinion on Drug Metabolism & Toxicology
keyword
keyword
30125
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"